Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus

Endocrine

Volumn 43, Issue 3, 2013, Pages 504-513

  Bergman, Michael ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes prevention; Glucolipotoxicity; Impaired fasting glucose; Impaired glucose tolerance; Incretin effect; Prediabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLYCOGEN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TROGLITAZONE; VOGLIBOSE;

BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISPOSITION INDEX; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; EXERCISE; FRACTURE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; GLUCOTOXICITY; GLYCOGEN SYNTHESIS; HEPATIC GLUCOSE OUTPUT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOTOXICITY; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC PARAMETERS; MOLECULAR PATHOLOGY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SKELETAL MUSCLE; TOXICITY; WEIGHT GAIN;

EID: 84877873090     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9830-9     Document Type: Review

References (64)

1. IDF, Diabetes Atlas Fourth Edition. International Diabetes Federation (Brussels, Belgium, 2009)
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20(7), 1183-1197 (1997)
3. The Expert Committee on the diagnosis and classification of diabetes mellitus, Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11), 3160-3167 (2003)
4. American Diabetes Association, Standards of medical care in diabetes-2012. Diabetes Care 35(1), S11-S63 (2012)
5. The International Expert Committee, International expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 32(7), 1327-1334 (2009)
6. WHO, Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. diabetes res. Clin. Pract. 93(3), 299-309 (2011)
7. Report of a WHO/IDF consultation: definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. WHO, Geneva, (2006). http://whqlibdoc.who.int/publications/2006/9241594934-eng.pdf
8. R.A. DeFronzo, M.A. Abdul-Ghani, Preservation of β-cell function: the key to diabetes prevention. J. Clin. Endocrinol. Metab. 96(8), 2354-2366 (2011)
9. J. Shaw, R.A. Sicree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4-14 (2010)
10. A.G. Tábak, C. Herder, W. Rathmann, E.J. Brunner, M. Kivimäki Prediabetes: a high-risk state for diabetes development. Lancet Published online June 9, (2012) doi: 10.1016/S0140-6736(12)60283-9
11. I. Hopper, B. Billah, M. Skiba, H. Krum, Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomized controlled clinical trials. Eur. J. Cardiovasc. Prev. Rehabil. 18(6), 813-823 (2011)
12. L. Perreault, Q. Pan, K.J. Mather, K.E. Watson, R.F. Hammam, S.E. Kahn, For the diabetes prevention program research group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study, Lancet published online June 9, (2012). (doi: 10.1016/S0140-6736(12)60525-X
13. A. Tirosh, I. Shai, D. Tekes-Manova, E. Israeli, D. Pereg, T. Shochat, I. Kochba, A. Rudich, For the Israeli diabetes research group, normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med. 353(10), 1454-1462 (2005)
14. M. Bergman, Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab. Res. Rev. 26(1), 5-6 (2010)
15. E. Ferrannini, M. Massari, M. Nannipieri, A. Natali, R.L. Ridaura, C. Gonzales-Villalpando, Plasma glucose levels as predictors of diabetes: the Mexico city diabetes study. Diabetologia 52(5), 818-824 (2009)
16. Y. Heianza, Y. Arase, K. Fujihara, H. Tsuji, K. Saito, S.D. Hsieh, S. Kodama, H. Shimano, N. Yamada, S. Hara, H. Sone, Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA1c and impaired fasting glucose the Toranomon hospital health management center study 4 (TOPCS 4). Diabetes Med. 29, e279-e285 (2012)
17. M.J. Picon, M. Murri, A. Muñoz, J.C. Fernandez-Garcia, R. Gomez-Huelgas, F.J. Tinahones, Hemoglobin A1c versus oral glucose tolerance test in postpartum diabetes screening. Diabetes Care 35(8), 1648-1653 (2012)
18. C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley, The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis if type 2 diabetes mellitus. J. Clin. Invest. 104(6), 787-794 (1999)
19. G.C. Weir, S. Bonner-Weir, Five stages of evolving β-cell dysfunction during progression to diabetes, Diabetes 53(12, suppl 3), S16-S21 (2004)
20. A. Vasudevan, A.J. Garber, Postprandial Hyperglycemia, in Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence-Based Approach to practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 97-113
21. C.H. Courtney, J.M. Olefsky, Insulin Resistance, in Mechanisms of Insulin Action, ed. by A.R. Saltiel, J.E. Pessin (Landes Bioscience and Springer Science + Business Media, New York, 2007), pp. 185-209
22. D.M. Muoio, T.R. Koves, J. An, C. Newgard, Metabolic Mechanisms of Muscle Insulin Resistance, in Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 97-113
23. R.N. Bergman, Banting Lecture 2006. Orchestration of glucose homeostasis, from a small acorn to the California Oak. Diabetes 56(6), 1489-1501 (2007)
24. M.A. Abdul-Ghani, M.P. Stern, V. Lyssenko, T. Tuomi, L. Groop, R.A. DeFronzo, Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care 33(3), 557-561 (2010)
25. D.A. Lang, D.R. Matthews, M. Burnett, R.C. Turner, Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 30(5), 435-439 (1981)
26. S. O'Rahilly, R.C. Turner, D.R. Matthews, Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N. Engl. J. Med. 318(19), 1225-1230 (1988)
27. M.M. Byrne, J. Sturis, R.J. Sobel, K.S. Polonsky, Elevated plasma 2 h post challenge predicts defects in beta-cell function. Am. J. Physiol. 270(4 pt1), E572-E579 (1996)
28. S. Seino, T. Shibasaki, K. Minami, Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J. Clin. Invest. 121(6), 2118-2125 (2011)
29. J.L. Leahy, Pathogenesis of Type 2 diabetes mellitus, in Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 17-33
30. A. Clark, Pancreatic Islet Pathology in Type 2 diabetes, in Pancreatic Beta Cell in Health and Disease, ed. by S. Seino, G.J. Bell (Springer, New York, 2008), pp. 381-398
31. A. Basu, M.G. Pedersen, C. Cobelli, Commentary. Prediabetes: evaluation of β-cell function. Diabetes 61(2), 270-271 (2012)
32. M.A. Abdul-Ghani, D. Tripathy, R.A. Defronzo, Contributions of β-Cell dysfunction and insulin resistance to the pathogenesis of Impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29(5), 1130-1139 (2006)
33. M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30(6), 1544-1548 (2007)
34. M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. DeFronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31(8), 1650-1655 (2008)
35. M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. DeFronzo, L. Groop, Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes:results from the Botnia Study. Diabetes Care 32(2), 281-286 (2009)
36. J.M. Haus, T.P.J. Solomon, C.M. Marchetti, J.M. Edmison, F. Gonzalez, J.P. Kirwan, Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J. Clin. Endocrinol. Metab. 95(1), 323-327 (2010)
37. E. Ferrannini, A. Gastaldelli, P. Iozzo, Pathophysiology of Prediabetes, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia, 2011), pp. 327-340
38. R.G. Mirmira, Saturated free fatty acids: islet β cell "stress ER". Endocrine 42(6), 1-2 (2012)
39. R. Weiss, S. Dufour, S.E. Taksali, W.V. Tamborlane, K.F. Petersen, R.C. Bonadonna, L. Boselli, G. Barbetta, K. Allen, F. Rife, M. savoye, J. Dziura, R. Sherwin, G.I. Shulman, S. Caprio, Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362, 951-957 (2003)
40. R.A. DeFronzo, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4), 773-795 (2009)
41. A. Vella, Mechanism of action of DPP-4 inhibitors-new insights. J. Clin. Endocrinol. Metab. 97(8), 2626-2628 (2012)
42. E. Muscelli, A. Casolaro, A. Gastaldelli, a Mari, G. Seghieri, B. Astiarraga, Y. Chen, M. alba, J. Holst, E. Ferrannini, Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J. Clin. Endocrinol. 97(8), 2818-2819 (2012)
43. M. Bergman, Treatment of prediabetes. Louvain Med 131(3), 104-113 (2012)
44. R.E. Ratner, A. Sathasivam, Treatment recommendations for prediabetes, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia PA., 2011), pp. 385-397
45. J. Armato, R.A. DeFronzo, M. Abdul-Ghani, R. Ruby, Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction. Endocr. Pract. 18(3), 342-350 (2012)
46. V. Aroda, R. Ratner, Approach to the patient with prediabetes. J. Clin. Endcorinol. Metab. 93(9), 3259-3265 (2008)
47. A. Ramachandran, C. Snehalatha, Diabetes Prevention Programs, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia PA, 2011), pp. 353-372
48. J.P. Crandall, W.C. Knowler, S.E. Kahn, D. Marrero, J.C. Florez, G.A. Bray, S. M. Haffner, M. Hoskin, D.M. Nathan, For the diabetes prevention program research group. Nat. Clin. Pract., www.nature.com/clinicalpractice, published online 20 May (2008). doi: 10.1038/ncpendmet0843
49. W.A. Hsueh, L. Orloski, K. Wyne, Prediabetes: the importance of early identification and intervention. Postgrad. Med. 122(4), 129-142 (2010)
50. D.M. Nathan, M.B. Davidson, R.A. DeFronzo, R.J. Heine, R.R. Henry, R. Pratley, B. Zinman, Impaired fasting glucose and impaired glucose tolerance: implications for care consensus statement from American diabetes association. Diabetes Care 30, 753-759 (2007)
51. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM trial research group, Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (2002)
52. R. Kawamori, N. Tajima, Y. Iwamoto, A. Kashiwagi, K. Shimamoto, K. Kaku, Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 1607-1614 (2009)
53. R. Moriya, T. Shirakura, J. Ito, S. Mashiko, T. Seo, Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am. J. Physiol. Endocrinol. Metab. 297, E1358-E1364 (2009)
54. Effect of nateglinide on the incidence of diabetes and cardiovascular events, Navigator study group. N. Engl. J. Med. 362(16), 1463-1476 (2010)
55. The ORIGIN Trial Investigators, Basal Insulin and Cardiovascular and Other Outcomes in dysglycemia. N. Engl. J. Med. 367(4), 319-328 (2012)
56. J. Segura, L.M. Ruilope, Treatment of prehypertension in diabetes and metabolic synderome: what are the pros? Diabetes Care 32(11, suppl 2), S284-S289 (2009)
57. L. Niskanen, T. Hedner, L. Hansson, J. Lanke, A. Niklason, For the CAPP study group. Diabetes Care 24(12), 2091-2096 (2001)
58. R. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108(suppl), 3B-24B (2011)
59. E.N. Taylor, F.B. Hu, G.C. Curhan, Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 29(5), 1065-1070 (2006)
60. C. Manrique, M. Johnson, J.R. Sowers, Thiazide diuretics alone or with β-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension 55(1), 15-17 (2010)
61. W.J. Elliott, P.M. Meyer, Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007)
62. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J.M. de Craen, S.R.K. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekhus, T.R. Perdersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375(9716), 735-742 (2010)
63. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, R.J. Glynn, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trail. Lancet 380(9841), 565-571 (2012)
64. A. Goldfine, Statins: is it really time to reassess benefits and risk? N. Engl. J. Med. 366(19), 1752-1755 (2012)